High frequencies of naive Melan-A/MART-1-specific CD8+ T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals

Journal of Experimental Medicine

Volumn 190, Issue 5, 1999, Pages 705-715

  Pittet, Mikaël J ^a   Valmori, Danila ^a   Dunbar, P Rod ^c   Speiser, Daniel E ^a   Liénard, Danielle ^a,b   Lejeune, Ferdy ^b   Fleischhauer, Katharina ^d   Cerundolo, Vincenzo ^c   Cerottini, Jean Charles ^a   Romero, Pedro ^a,b  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Immunotherapy; Influenza matrix; Melanoma; Tetramer; Tumor immunity

Indexed keywords

GAMMA INTERFERON; HLA A2 ANTIGEN; MELANOMA ANTIGEN;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN TISSUE; INFLUENZA VIRUS; MELANOMA; PHENOTYPE; PRIORITY JOURNAL; TUMOR IMMUNITY;

ADULT; AGED; ANTIGENS, NEOPLASM; CASE-CONTROL STUDIES; CD8-POSITIVE T-LYMPHOCYTES; HLA-A2 ANTIGEN; HUMANS; IMMUNOLOGIC MEMORY; INTERFERON TYPE II; LYMPHOCYTE COUNT; MELANOMA; MIDDLE AGED; NEOPLASM PROTEINS; PHENOTYPE; PROTEIN CONFORMATION; TIME FACTORS;

EID: 0032819985     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.190.5.705     Document Type: Article

References (48)

1. Robbins, P.F., and Y. Kawakami. 1996. Human tumor antigens recognized by T cells. Curr. Opin. Immunol. 8:628-636.
2. Romero, P. 1996. Cytolytic T lymphocyte responses of cancer patients to tumor-associated antigens. Springer Semin. Immunopathol. 18:185-198.
3. Pardoll, D.M. 1998. Cancer vaccines. Nat. Med. 4:525-531.
4. Coulie, P.G., V. Brichard, A. Van Pel, T. Wolfel, J. Schneider, C. Traversari, S. Mattei, E. De Plaen, C. Lurquin, J.P. Szikora, et al. 1994. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp. Med. 180:35-42.
5. Kawakami, Y., S. Eliyahu, C.H. Delgado, P.F. Robbins, L. Rivoltini, S.L. Topalian, T. Miki, and S.A. Rosenberg. 1994. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA. 91:3515-3519.
6. Rivoltini, L., Y. Kawakami, K. Sakaguchi, S. Southwood, A. Sette, P.F. Robbins, F.M. Marincola, M.L. Salgaller, J.R. Yannelli, E. Appella, and S.A. Rosenberg. 1995. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J. Immunol. 154:2257-2265.
7. Jäeger, E., H. Bernhard, P. Romero, M. Ringhoffer, M. Arand, J. Karbach, C. Ilsemann, M. Hagedorn, and A. Knuth. 1996. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. Int. J. Cancer. 66:162-169.
8. + melanoma patients have a memory phenotype. Int. J. Cancer. 78: 699-706.
9. Marincola, F.M., L. Rivoltini, M.L. Salgaller, M. Player, and S.A. Rosenberg. 1996. Differential anti-MART-1/Melan-A CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells. J. Immunother. Emphasis Tumor Immunol. 19:266-277.
10. Romero, P., J.C. Cerottini, and G.A. Waanders. 1998. Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy. mol. Med. Today. 4:305-312.
11. Favre, F., J. Even, and P. Kourilsky. 1998. Tumor-specific immune response: current in vitro analyses may not reflect the in vivo immune status. Crit. Rev. Immunol. 18:77-86.
12. Romero, P., P.R. Dunbar, D. Valmori, M. Pittet, G.S. Ogg, D. Rimoldi, J.L. Chen, D. Liénard, J.C. Cerottini, and V. Cerundolo. 1998. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytotoxic T lymphocytes J. Exp. Med. 188:1641-1650.
13. Merkenschlager, M., and P.C. Beverley. 1989. Evidence for differential expression of CD45 isoforms by precursors for memory-dependent and independent cytotoxic responses: human CD8 memory CTLp selectively express CD45RO (UCHL1). Int. Immunol. 1:450-459.
14. + cells with different requirements for activation and differentiation. J. Immunol. 146:2088-2094.
15. bright T cell subsets and their relationship to memory and naive T cells. Eur. J. Immunol. 27:2383-2390.
16. Roederer, M., J.G. Dubs, M.T. Anderson, P.A. Raju, and L.A. Herzenberg. 1995. CD8 naive T cell counts decrease progressively in HIV-infected adults. J. Clin. Invest. 95:2061-2066.
17. + T cells contain cells with high levels of lymphocyte function-associated antigen-1 expression, a phenotype of primed T cells. J. Immunol. 150:429-437.
18. + T-cell memory, CD45R subsets and the persistence of antigen - a unifying concept. Immunol. Today. 19:60-64.
19. - T lymphocytes. Antigenic and functional properties. J. Immunol. 150:1147-1159.
20. - T cells in healthy ageing people, including centenarians. Immunology. 88:501-507.
21. Berthou, C., S. Legros-Maïda, A. Soulié, A. Wargnier, J. Guillet, C. Rabian, E. Gluckman, and M. Sasportes. 1995. Cord blood T lymphocytes lack constitutive perform expression in contrast to adult peripheral blood T lymphocytes. Blood. 85:1540-1546.
22. + T cells. J. Exp. Med. 186:1407-1418.
23. - cytotoxic effector clones. Int. Immunol. 11:229-241.
24. + T-cell development. Immunol. Today. 4:177-180.
25. Lehner, P.J., E.C. Wang, P.A. Moss, S. Williams, K. Platt, S.M. Friedman, J.I. Bell, and L.K. Borysiewicz. 1995. Human HLA-A0201-restricted cytotoxic T lymphocyte recognition of influenza A is dominated by T cells bearing the Vβ17 gene segment. J. Exp. Med. 181:79-91.
26. Altman, J.D., P.A.H. Moss, P.J.R. Goulder, D.H. Barouch, M.G. McHeyzer-Williams, J.I. Bell, A.J. McMichael, and M.M. Davis. 1996. Phenotypic analysis of antigen-specific T lymphocytes. Science. 274:94-96.
27. Parham, P., and F.M. Brodsky. 1981. Partial purification and some properties of BB7.2, a cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28. Hum. Immunol. 3:277-284.
28. Fleischhauer, K., E. Zino, M. Arevalo-Herrera, S. Herrera, D. Valmori, J.C. Cerottini, E. Benazzi, C. Bordignon and P. Romero. 1998. Differential expression of HLA-A*02 subtypes in Colombian Blacks and Mestizos. Tissue Antigens. 51: 204-209.
29. Skipper, J.C.A., R.C. Hendrickson, P.H. Gulden, V. Brichard, A. Van Pel, Y. Chen, J. Shabanowitz, T. Wölfel, C.L. Slingluff, Jr., T. Boon, et al. 1996. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J. Exp. Med. 183:527-534.
30. Romero, P., N. Gervois, J. Schneider, P. Escobar, D. Valmori, C. Pannetier, A. Steinle, T. Wölfel, D. Liénard, V. Brichard, et al. 1997. Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201 restricted Melan-A/ MART-1 antigenic peptide in melanoma. J. Immunol. 159: 2366-2374.
31. Valmori, D., J.-F. Fonteneau, C.M. Lizana, N. Gervois, D. Liénard, D. Rimoldi, V. Jongeneel, F. Jotereau, J.C. Cerottini, and P. Romero. 1998. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J. Immunol. 160:1750-1758.
32. Men, Y., I. Miconnet, D. Valmori, J.C. Cerottini, and P. Romero. 1999. Assessment of immunogenicity of human Melan-A peptide analogues in HLA-A*0201/Kb transgenic mice. J. Immunol. 162:3566-3573.
33. Taswell, C. 1981. Limiting dilution analysis for the determination of immunocompetent cell frequencies. I. Data analysis. J. Immunol. 126:1614-1619.
34. Valmori, D., MJ. Pitter, C. Vonarbourg, D. Rimoldi, D. Liénard, D. Speiser, R. Dunbar, V. Cerundolo, J.C. Cerottini, and P. Romero. 1999. Analysis of the cytolytic T lymphocyte response of melanoma patients to the naturally HLA-A*0201-associated tyrosone peptide 368-376. Cancer Res. In press.
35. Ogg, G.S., P.R. Dunbar, P. Romero, J. Chen, and V. Cerundolo. 1998. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J. Exp. Med. 188:1203-1208.
36. McMichael, A.J., and C.A. O'Callaghan. 1998. A new look at T cells. J. Exp. Med. 187:1367-1371.
37. van Elsas, A., S.H. van der Burg, C.E. van der Minne, M. Borghi, J.S. Mourer, C.J.M. Melief, and P.I. Schrier. 1996. Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A *0201 binding peptides from the Melan-A/MART-1 self antigen. Eur. J. Immnnol. 26:1683-1689.
38. Unutmaz, D., P. Pileri, and S. Abrignani. 1994. Antigen-independent activation of naive and memory resting T cells by a cytokine combination. J. Exp. Med. 180:1159-1164.
39. Dutton, R.W., L.M. Bradley, and S.L. Swain. 1998. T cell memory. Annu. Rev. Immunol. 16:201-223.
40. (27-35). J. Exp. Med. 184:647-657.
41. + T cell line. J. Immunol. 146:1175-1183.
42. + naive CD4 T cells. Immunology. 91:323-330.
43. Tanchot, C., and B. Rocha. 1998. The organization of mature T-cell pools. Immunol. Today. 19:575-579.
44. + thymic emigrants. J. Immunol. 160:3705-3712.
45. Nordlund, J.J., J.M. Kirkwood, B.M. Forget, G. Milton, D.M. Albert, and A.B. Lerner. 1983. Vitiligo in patients with metastatic melanoma: a good prognostic sign. J. Am. Acad. Derm. 9:689-696.
46. Song, Y.-H., E. Conner, Y. Li, B. Zorovich, P. Balducci, and N. Maclaren. 1994. The role of tyrosinase in autoimmune vitiligo. Lancet. 344:1049-1052.
47. Rosenberg, S.A., and D.E. White. 1996. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J. Immunotherapy. 19:81-84.
48. Valmori, D., M.J. Pittet, D. Rimoldi, D. Liénard, R. Dunbar, V. Cerundolo, F. Lejeune, J.C. Cerottini, and P. Romero. 1999. An antigen-targeted approach to adoptive transfer therapy of cancer. Cancer Res. 59:2167-2173.